Skullcandy Inc. (SKUL) Jumps 5.28% on January 29

Equities Staff  |

Skullcandy Inc. (SKUL) was among the biggest gainers on the Russell 2000 for Friday January 29 as the stock popped 5.28% to $3.19, representing a gain of $0.16 per share. Some 184,316 shares traded hands on 735 trades, compared with an average daily volume of 295,589 shares out of a total float of 28.53 million. The stock opened at $3.02 and traded with an intraday range of $3.20 to $2.99.

After today's gains, Skullcandy Inc. reached a market cap of $91.01 million. Skullcandy Inc. has had a trading range between $11.83 and $2.75 over the last year, and it had a 50-day SMA of $4.08 and a 200-day SMA of $6.53.

The stock has a P/E Ratio of 12.5.

Skullcandy Inc designs, markets and distributes audio and gaming headphones, earbuds, speakers and other accessories under the Skullcandy, Astro Gaming and 2XL brands. The Company operates through its Domestic and International segment.

Skullcandy Inc. is based out of Park City, UT and has some 300 employees. Its CEO is Hoby Darling.

For a complete fundamental analysis analysis of Skullcandy Inc., check out’s Stock Valuation Analysis report for SKUL. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Crypto World in Review: Taking in the Good with the Bad

A lot happened in the cryptocurrency industry this week.

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.